Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 2 years of age;~2. Have sickle cell disease (confirmed by Hb electrophoresis or more specific tests) or other conditions with iron overload from repeated blood transfusions (see exclusion criteria for exceptions);~3. Baseline LIC \>7 mg/g dw (measured by MRI);~4. Patients who have received no less than 20 transfusions of RBCs;~5. Patients who have received at least 1 transfusion per year in the last 2 years and who are expected to have a continuing requirement (based on Investigator's judgement) during the duration of the trial~Exclusion Criteria:~1. Thalassemia syndromes;~2. Myelodysplastic syndrome (MDS) or myelofibrosis;~3. Diamond Blackfan anemia;~4. Primary bone marrow failure;~5. Baseline LIC \>30 mg/g dw (measured by MRI);~6. Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;~7. Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events;~8. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;~9. Treated with hydroxyurea within 30 days;~10. History of malignancy;~11. Evidence of abnormal liver function (serum ALT level(s) \> 5 times upper limit of normal at screening or creatinine levels \>2 times upper limit of normal at screening);~12. A serious, unstable illness, as judged by the Investigator, during the past 3 months before screening/baseline visit including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease;~13. Clinically significant abnormal 12-lead ECG findings;~14. Cardiac MRI T2\* \<10ms;~15. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening/baseline visit;~16. Unable to undergo MRI~17. Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferiprone (Type: EXPERIMENTAL): Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
- Deferoxamine (Type: ACTIVE_COMPARATOR): Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.

Based on this trial design, predict the completion outcome and termination type (if applicable).